Journal article icon

Journal article

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Abstract:

While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30-40% reductions in heart failure hospitalisation, cardiovascular and all-cause deaths on empagliflozin were highly impressive and unexpected. In this review, we discuss briefly why cardiovascular end-point trials for new diabetes agents were required and describe the results of the first four such trials to have reported as a p...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1007/s00125-016-3956-x

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
Publisher:
Springer
Journal:
Diabetologia More from this journal
Publication date:
2016-04-01
Acceptance date:
2016-03-29
DOI:
EISSN:
1432-0428
ISSN:
0012-186X
Keywords:
Pubs id:
pubs:618078
UUID:
uuid:fc6c809f-50df-42dc-b1f8-99ec9340de42
Local pid:
pubs:618078
Source identifiers:
618078
Deposit date:
2016-04-28

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP